Biologics in Psoriatic Patients with Malignancies: Where Are We Now? an Italian Multicentric Study

Journal of the European Academy of Dermatology and VenereologyEarly View LETTER TO THE EDITOR Biologics in psoriatic patients with malignancies: Where are we now? An Italian multicentric study M. Magnano, Corresponding Author M. Magnano [email protected] orcid.org/0000-0001-9429-9004 Division of Dermatology, APSS-Trento Hospital, Trento, Italy Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Correspondence M. Magnano, Division of Dermatology, Santa Chiara Hospital, Largo Medaglie d'Oro 9, Trento 38122, Italy. Email: [email protected]Search for more papers by this authorR. Balestri, R. Balestri orcid.org/0000-0002-0885-054X Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this authorP. Gisondi, P. Gisondi orcid.org/0000-0002-1777-9001 Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalySearch for more papers by this authorF. Bardazzi, F. Bardazzi Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalySearch for more papers by this authorV. Di Lernia, V. Di Lernia Division of Dermatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalySearch for more papers by this authorT. Ioris, T. Ioris Division of Dermatology, APSS-Trento Hospital, Trento, Italy Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalySearch for more papers by this authorC. R. Girardelli, C. R. Girardelli Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this authorG. Rech, G. Rech Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this author M. Magnano, Corresponding Author M. Magnano [email protected] orcid.org/0000-0001-9429-9004 Division of Dermatology, APSS-Trento Hospital, Trento, Italy Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Correspondence M. Magnano, Division of Dermatology, Santa Chiara Hospital, Largo Medaglie d'Oro 9, Trento 38122, Italy. Email: [email protected]Search for more papers by this authorR. Balestri, R. Balestri orcid.org/0000-0002-0885-054X Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this authorP. Gisondi, P. Gisondi orcid.org/0000-0002-1777-9001 Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalySearch for more papers by this authorF. Bardazzi, F. Bardazzi Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalySearch for more papers by this authorV. Di Lernia, V. Di Lernia Division of Dermatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalySearch for more papers by this authorT. Ioris, T. Ioris Division of Dermatology, APSS-Trento Hospital, Trento, Italy Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalySearch for more papers by this authorC. R. Girardelli, C. R. Girardelli Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this authorG. Rech, G. Rech Division of Dermatology, APSS-Trento Hospital, Trento, ItalySearch for more papers by this author First published: 01 November 2023 https://doi.org/10.1111/jdv.19603 M. Magnano and R. Balestri contributed equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017; 177(3): 628–636. 10.1111/bjd.15665 CASPubMedWeb of Science®Google Scholar 2Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021; 35(2): 281–317. 10.1111/jdv.16926 CASPubMedWeb of Science®Google Scholar 3Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016; 151(1): 97–109.e4. 10.1053/j.gastro.2016.03.037 PubMedWeb of Science®Google Scholar 4Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni RG, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat. 2022; 33(3): 1638–1642. 10.1080/09546634.2021.1886231 CASPubMedWeb of Science®Google Scholar 5Odorici G, Lasagni C, Bigi L, Pellacani G, Conti A. A real-life experience of psoriatic patients with history of cancer treated with biological drugs. J Eur Acad Dermatol Venereol. 2019; 33(12): e453–e455. 10.1111/jdv.15775 CASPubMedWeb of Science®Google Scholar 6Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P, et al. Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 2022; 12(11): 2613–2626. 10.1007/s13555-022-00797-9 PubMedWeb of Science®Google Scholar 7Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatolog Treat. 2022; 33(5): 2495–2502. 10.1080/09546634.2021.1970706 PubMedWeb of Science®Google Scholar 8Vitiello GA, Miller G. Targeting the interleukin-17 immune axis for cancer immunotherapy. J Exp Med. 2020; 217(1):e20190456. 10.1084/jem.20190456 PubMedWeb of Science®Google Scholar 9Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9): 585–600. 10.1038/nri3707 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation